Kechun Li


Mingxin China Growth Fund

As a partner of Mingxin China Growth Fund, Mr. Li is in charge of medical investment. When serving as the general manager of Chiral Quest Inc. (China), he invested 5 million dollars to complete MBO, 13 million dollars and 120 million yuan to create Suzhou branch. Li Kechun is also an experienced and successful chemist, playing an important role in novel anticancer agent Halaven and E5531 for antiseptics, whose annual sale can reach 300 million dollars.

Mingxin China Growth Fund is an international private equity investment fund. Currently the funds under our management are as follows: Mingxin China Growth Fund I (formerly Mingly China Growth Fund) (USD Fund I), Govtor Mingly Growth Venture Capital Company Limited (RMB Fund I), Mingxin China Growth Fund II (USD Fund II). These funds are committed to making critical growth and expansion stage investments in China. It also established Yantai Venture Capital Investment Co., Ltd. in Yantai with Yantai Municipal Government and Hongda Fund. Advantages: The Fund Management Team and its Advisors include a collaboration of successful and experienced U.S. and Chinese investment professionals; Demonstrated ability to identify sector leaders and willingness to cooperate with portfolio founders; Experience from continuously successful investments and active approach to help companies succeed in future; Hands-on operating experience to help enhance management and operation ability; Global network of contacts to assist with technology, sales and marketing and management expertise; Both Foreign Currency Fund and RMB Fund to meet financing needs of various companies.